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Up to a third of strokes are rendered cryptogenic or of undetermined etiology. This 
number is specifically higher in younger patients. At times, inadequate diagnostic 
workups, multiple causes, or an under-recognized etiology contributes to this statistic. 
Embolic stroke of undetermined source, a new clinical entity particularly refers to patients 
with embolic stroke for whom the etiology of embolism remains unidentified despite 
through investigations ruling out established cardiac and vascular sources. In this article, 
we review current classification and discuss important clinical considerations in these 
patients; highlighting cardiac arrhythmias and structural abnormalities, patent foramen 
ovale, paradoxical sources, and potentially under-recognized, vascular, inflammatory, 
autoimmune, and hematologic sources in relation to clinical practice.
Keywords: cryptogenic stroke, embolic stroke of undetermined source, patent foramen ovale, paroxysmal atrial 
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DeFiNiTiON, CLASSiFiCATiON, AND RiSK
Approximately one-third of all ischemic strokes are of undetermined etiology and are more prevalent 
among young adults (1–3). The term “cryptogenic stroke” (CS) has been extensively used in the 
literature to describe this subtype. However, this does not take into account the extent and quality of 
the investigation performed or classification system used. In the TOAST classification system, stroke 
of undetermined cause may refer to a stroke with incomplete workup, more than one potential cause, 
or indeed no determined etiology after investigations are complete (4). In the ASCO classification, 
cause is completely unknown when stroke subtyping does not confer to atherosclerosis (A), small 
vessel disease (S), cardiac disease (C), or other cause (O) (5). This allows for potential misclassifica-
tion and overrepresentation of CS using these systems. In some instances, young stroke patients 
have been classified as cardioembolic based on the finding of a patent foramen ovale (PFO) (6). 
Furthermore, patients with few traditional risk factors may be classified as cryptogenic. However, 
clinical, radiographic, and risk factor profiles vary. Thorough etiological investigations and appropri-
ate classification are needed to best categorize these patients.
In 2014, the term Embolic stroke of undetermined source (ESUS) was coined by the CS/ESUS inter-
national working group (7). ESUS refers to non-lacunar infarct (subcortical infarct ≤1.5 cm on CT 
or ≤2.0 cm on MRI) in the absence the following: extracranial or intracranial atherosclerosis causing 
>50% luminal stenosis in the artery supplying the ischemic region, major cardiomebolic sources 
[permanent or paroxysmal atrial fibrillation (AF), sustained atrial flutter, intracardiac thrombus, 
prosthetic cardiac valve, atrial myxoma or other cardiac tumors, mitral stenosis, myocardial infarction 
within the past 4 weeks, left ventricular (LV) ejection fraction <30%, valvular vegetation’s or infective 
endocarditis], and no other specific cause of stroke (e.g., dissection, arteritis, migraine/vasospasm, 
TABLe 1 | Cardiac monitoring for detection of atrial fibrillation in eSUS and CS.
Type of monitoring Setting invasive vs. non-invasive Duration Rate of detection of atrial fibrillation (%)
Observational/retrospective studies
Admission ECG Inpatient Non-invasive N/A 2.7
Inpatient continuous telemetry Inpatient Non-invasive 3–5 days 5.5–7.6
Holter monitor Outpatient Non-invasive 24–48 h 3.2–6.4
Mobile continuous outpatient telemetry Outpatient Non-invasive 21–30 days 16–25
Implantable loop recorders Outpatient Invasive 6–18 months 20–30
Randomized clinical trials
Mobile continuous outpatient telemetry Outpatient Non-invasive 28 days 16.2
Implantable cardiac monitor Outpatient Invasive 6–36 months 9–30
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drug misuse). This allows a more comprehensive investigation and 
exclusion of presumed non-embolic stroke mechanisms during 
evaluation. Due to the novelty of this term, studies in the literature 
have mostly used the term CS, which may include patient fulfilling 
ESUS criteria.
Patients with CS, and especially the young, typically lack 
traditional stroke risk factors (3). Although recurrent stroke 
in patients with CS and ESUS varies, the risk remains high. In 
a recent population-based study including 2555 patients, the 
10-year risk of recurrence in CS vs. non-cardioembolic stroke was 
32 vs. 27% (p = 0.91). Moreover, compared with large and small 
vessel disease subtypes combined, patients with CS had no excess 
of minor-risk echocardiographic abnormalities, paroxysmal AF 
at baseline or new onset AF, or presumed cardioembolic events 
during follow-up (3). In the Athens Stroke Registry, stroke recur-
rence in ESUS patients was also high (29.0%) similar to recur-
rence risk of cardioembolic stroke (26%) and significantly higher 
as compared to all other non-cardioembolic stroke subtypes (8).
POSSiBLe eTiOLOGieS OF eSUS AND CS
Cardiac Atrial Fibrillation and  
Cryptogenic Stroke
Atrial fibrillation has been considered to be a precursor for left 
atrial stasis, thrombus formation, and subsequent embolism 
where treatment with anticoagulation therapy has been shown 
to be superior to antiplatelet therapy in reducing the embolic 
risk (9). Since AF can be paroxysmal, there has been growing 
evidence to support outpatient cardiac monitoring to increase 
the detection of AF in patients with CS, which culminated in 
two randomized trials proving an increase in detection rates with 
prolonged monitoring when compared to standard of care.
The EMBRACE trial randomized 572 patients with CS or 
transient ischemic attack to standard 24-h Holter monitor vs. 
30-day outpatient event-triggered monitor. The primary outcome 
was 30 s of AF detected at 90 days. In this study, the detection rate 
was significantly higher in patients receiving 30 day monitoring 
compared to 24 h telemetry (16.1 vs. 3.2%, P < 0.001) (10). On 
the other hand, the CRYSTAL-AF study randomized 441 patients 
with CS or TIA to long-term monitoring with REVEAL implant-
able cardiac monitor (ICM) vs. standard of care. The primary 
outcome was first detection of AF at 6 months. AF was detected 
at a rate of 8.9% of patients in the ICM group, as compared with 
1.4% in the control group, yielding a hazard ratio of 6.4 (95% 
CI, 1.9–21.7; P  <  0.001). There was an incremental increase 
in the detection rate with time yielding a hazard ratio of 8.78 
(3.47–22.19) at 3  years (11). The reason for differences in 
the detection rates between the two studies remains unclear. 
However, this may be due to differences in the study populations, 
stroke diagnostic evaluation, and inclusion and exclusion criteria. 
Results of these trials suggest a robust role for outpatient cardiac 
monitoring after a CS and the longer patients are monitored, the 
higher the yield of detecting AF. It remains unclear, however, what 
the optimal monitoring duration and modality is. The rate of AF 
detection varies between 2.7 and 30% depending on duration and 
modality of monitoring (Table 1) (12).
Several predictors of AF detection in patients with CS have 
been identified. Older age (13) and prior embolic infarcts (13, 14) 
were the most robust clinical and radiological predictor of AF that 
were identified in studies. In addition, cardiac predictors included 
left atrial enlargement on echocardiogram and premature atrial 
complex on ECG or inpatient cardiac telemetry (15, 16). Based on 
current evidence, starting with the 30-day non-invasive cardiac 
monitoring is a reasonable first approach. If AF is not detected, 
prolonged monitoring with ICM may be considered.
Atrial “Cardiopathy” and Cryptogenic Stroke
For long, it has been proposed that the fibrillating left atrium is a 
precursor for thrombus formation and cardioembolism. Recent 
evidence, however, challenges the concept that AF by itself is 
the direct cause of thromboembolic events in these patients. 
The ASSERT study enrolled 2580 patients who were 65 years or 
older with a history of hypertension and without known AF who 
underwent cardiac pacemaker implantation and monitored them 
for 2.5 years. This study showed that subclinical AF was detected in 
approximately 10% of patients at 3 months and only 15% of them 
developed clinical AF. In addition, subclinical AF was predictive 
of ischemic stroke or systemic embolism risk (adjusted hazard 
ratio 2.50; 95% CI, 1.28–4.89; P = 0.008) (16). In this study, of 
the 51 patients who had ischemic stroke or systemic embolism, 
26 (51%) had subclinical AF >6 min, and of these patients, 18 
had AF detected prior to the event but only 4 patients had it in 
the 30 days preceding the event. The rest had AF for the first time 
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after the embolic event. These findings and findings from another 
study (17) suggest lack of a temporal relationship between sub-
clinical AF and embolic events, challenging the old concept that 
AF is the major determinant of embolic risk in patients with this 
dysrhythmia (16, 18). The findings rather suggest that AF may be 
a marker of atrial dysfunction (19) or “cardiopathy,” which in turn 
is the direct cause of embolic events in these patients.
Furthermore, there is growing evidence to suggest an associa-
tion between biomarkers of atrial dysfunction or cardiopathy and 
ischemic stroke independent of AF. Electrocardiogram (ECG) 
parameters of left atrial dysfunction have been shown to be 
associated with ischemic stroke risk. In a study using a statewide 
administrative database, when compared to matched controls, 
patients with supraventricular tachycardia were shown to have 
a twofold increase in risk of ischemic stroke (hazard ratio, 2.10; 
95% confidence interval, 1.69–2.62) (20, 21). In population-based 
cohorts, p-wave dispersion on ECG, another marker of left atrial 
dysfunction, was shown to be associated with ischemic stroke risk 
(22), especially those of embolic subtype (23).
Serum N-terminal pro-BNP is a biomarker that can be elevated 
in patients with heart failure and atrial stretch and predicts inci-
dent of AF (24). Several studies showed an association between 
serum NT-proBNP level and ischemic stroke risk (especially 
those of embolic subtype), a relationship independent of baseline 
or incident AF (16, 25, 26). In addition, left atrial enlargement 
on echocardiogram can lead to stasis, thrombus formation, 
and embolic events. Recently, an analysis from the Northern 
Manhattan Stroke Study showed an association between moder-
ate to severe left atrial enlargement and recurrent embolic stroke 
independent of AF (21).
Since AF can be paroxysmal and difficult to diagnose even after 
prolonged monitoring and since recent studies suggest the lack of 
causality between AF and embolic events, it may be appealing to 
look for more permanent biomarkers in CS patients with an aim 
to evaluate left atrial function and understand the risk of stroke 
recurrence. A recent analysis from the SPOTRIAS data showed 
that biomarkers of atrial cardiopathy can be present in up to 
65% of patients with CS and these biomarkers were associated 
with vascular risk factors and inversely associated with other 
potential stroke mechanisms such as PFO (27). Since long-term 
monitoring for AF was not performed routinely in these studies, 
it remains unclear whether or not this association is mediated by 
the presence of subclinical paroxysmal AF despite the relation-
ship between biomarkers of atrial cardiopathy and stroke risk.
Patients with CS who have evidence of atrial cardiopathy 
may therefore constitute a group where anticoagulation therapy 
may be superior to antiplatelet therapy in reducing the risk of 
recurrent stroke. In fact, while the WARSS study did not show 
any benefit of warfarin over aspirin in reducing the 2-year risk 
of stroke or death, a post  hoc analysis of WARSS showed that 
in patients with NT-proBNP >750 ng/dL, a biomarker of atrial 
cardiopathy, warfarin was superior to aspirin in reducing the risk 
of stroke or death at 2 years (28).
Patent Foramen Ovale
Patent foramen ovale is the most common congenital cardiac 
abnormality present in approximately 25% of the population 
(29) and responsible for up to 95% of right-to-left shunts (30). 
PFO prevalence among patients with CS are typically high with 
median prevalence of approximately 40% (31) and more com-
monly present in the young (31, 32). A meta-analysis of 23 studies 
evaluating CS and PFO’s concluded the odds of finding a PFO is 
2.9 times higher in patients with CS as compared to control sub-
jects (31). Several PFO characteristics with a higher probability 
for thromboembolism have been suggested. Atrial septal aneu-
rysm has been most commonly reported; as incidence is higher 
among both older and younger patients with CS (33) Excursion 
of ≥10 mm of the interatrial septum during the cardiac cycle has 
been associated with increased risk of recurrent stroke (34). In 
addition, severe left-to-right shunt and large opening of PFO have 
also been proposed (35). However, these and other anatomic and 
physiologic findings such as shunting without Valsalva, Chiari 
network, and prominent Eustichian valves have shown inconsist-
ent findings regarding stroke recurrence (34).
Patients are usually unaware of having a PFO until discovered 
during diagnostic evaluation for stroke etiology. Saline contrast 
injection or agitated saline mixed with air (also referred to as a 
“bubble study”) during TTE or TEE can detect a PFO if microbub-
bles are seen within the left atrial chamber within three cardiac 
cycles after right atrial opacification (29).
Directly establishing the PFO as the source of stroke is chal-
lenging. In situ thrombus formation and propensity for cardiac 
arrhythmias in these patients have been suggested mechanisms 
(36). Although cases of direct visualization of thrombus within 
the PFO have been reported (37), it is rarely observed. By far, 
paradoxical embolization is the most commonly proposed 
mechanism for stroke. Therefore, finding a proximal source such 
as a deep venous thrombus (DVT) is warranted, otherwise the 
association is rendered theoretical.
The reported frequency of DVT detection in patients with PFO 
and stroke has been 7.6–9.5% (32, 38, 39). Of major importance, 
in one study 80% of DVT’s detected were asymptomatic, empha-
sizing the need of ultrasound phlebography in patients with PFO 
and stroke of unknown source (32). With an advantage above 
ultrasound, magnetic resonance venography (MRV) can help 
detect isolated pelvic DVT’s. Although considered a rare entity, 
isolated pelvic thrombi have been seen in up to 20% of patients 
with suspected DVT (40). In contrast, the reported diagnostic 
yield for pelvic DVT in the setting of PFO and CS has varied 
between 1.5 and 13% (38, 39, 41). Of importance, DVT’s may 
develop due to the bed-ridden status of stroke patients therefore 
caution in interpreting this finding is warranted, particularly if 
discovered days after stroke onset. The suggestion of the role of 
PFO is CS has been postulated in cases of stroke with concomi-
tant pulmonary embolism or myocardial infarction supporting a 
paradoxical embolic mechanism.
Beyond evaluation for DVT’s, pelvic MRV can help detect 
compression of the left iliac vein against the lumbar vertebra 
by the overlying right common iliac artery, known as the 
May–Thurner syndrome (42). Also known as iliocaval compres-
sion, the prevalence of this anatomical variant is roughly 20% 
and is more common among women (43). Although rarely 
symptomatic, May–Thurner syndrome as a plausible cause of 
paradoxical embolism in CS and PFO has a reported prevalence 
TABLe 3 | PFO prevalence, attributable fraction and estimated 2-year risk of stroke or TiA by points strata (using a control rate of 25%) (45).
CS (n = 3023) CS with PFO (n = 1324)
RoPe 
score
No. of 
patients
Prevelence of patients with  
a PF (95% Ci)
PFO-attributable fraction, 
% (95% Ci)
estimated 2-year stroke/TiA recurrence rate,  
% (95% Ci)
0–3 613 23 (19–26) 0 (0–4) 20 (12–28)
4 511 35 (31–39) 38 (25–48) 12 (6–18)
5 516 34 (30–38) 34 (21–45) 7 (3–11)
6 482 47 (42–51) 62 (21–45) 8 (4–12)
7 434 54 (49–59) 72 (66–76) 6 (2–10)
8 287 67 (62–73) 84 (79–87) 6 (2–10)
9 180 73 (66–79) 88 (83–91) 2 (0–4)
TABLe 2 | Risk of paradoxical embolism score calculator (45).
Characteristic Points
No history of hypertension 1
No history of diabetes 1
No history of stroke or TIA 1
Non-smoker 1
Cortical infarct on imaging 1
Age (years)
18–29 5
30–39 4
40–49 3
50–59 2
60–69 1
≥70 0
Total score (sum of individual points)
Maximum score (a patient <30 years with no hypertension, no 
diabetes, no history of stroke or TIA, non-smoker, and cortical 
infarct)
10
Minimum score (a patient ≥70 years with hypertension, diabetes 
prior stroke, current smoker, and no cortical infarct)
0
4
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of 6.3% (44). Albeit an interesting finding, further studies are 
needed to evaluate the true role of May–Thurner syndrome in 
PFO-associated stroke.
Establishing the relationship between PFO and stroke is also 
challenging. A simple tool, the Risk of Paradoxical Embolism 
(ROPE) score has been proposed to risk stratify patients by 
age, and presence or absence of traditional vascular risk factors 
(45). Using clinical and radiological data of over 3000 patients, a 
multivariate regression model identified six variables associated 
with PFO status. A 10-point scale was created that can stratify the 
probability of a discovered PFO to be incidental or stroke related 
(Table 2). High ROPE scores are observed in younger patients 
with little or no traditional risk factors and superficially located 
infarcts, while low scores are observed in older patients with deep 
infarcts and traditional risk factors. In addition, an estimated 
2-year risk of stroke or TIA was calculated for each group. Patients 
with higher probability of PFO-related stroke (ROPE scores 
7–10) had the lowest recurrence rates (2–6%) while patients with 
lowest probability of PFO-related stroke (ROPE score 0–3) had 
the highest recurrence rate (20%) (Table 3) (45). These findings 
support the fact that patients with traditional stroke risk factors 
are more likely to have a PFO on their diagnostic workup as a 
“casual” relationship, rather than causal one.
Patients with PFO, stroke and DVT should be anticoagulated, 
provided the risk of anticoagulation including bleeding and/or 
hemorrhagic transformation of an ischemic infarction does not 
outweigh the benefit of recurrent stroke. In such condition, and 
inferior vena cava filter may be considered (46). Endovascular 
management and reconstruction of occluded iliac veins in May–
Thurner syndrome has low reported complication rates and is 
feasible in most cases (47). However, given the lack of randomized 
control trials in the setting of CS and PFO, careful consideration 
regarding optimal management is warranted, as true risk benefit 
has not been elucidated.
Current evidence-based guidelines do not support routine 
closure of PFO in the absence of DVT or proximal source and 
recommend antiplatelet therapy (46). Three major randomized 
controlled trials did not show a net benefit from closure of PFO 
in this population (48–50). A meta-analysis evaluating these 3 
and an additional 11 non-randomized observational studies 
failed to prove superiority of closure against medical therapy, 
with an increased incidence of new onset AF in the closure group 
(RR 3.50) (51). However, it should be noted that previous PFO 
closure trials differed in study criteria, devices used, and lack of 
standardized design. Ongoing trials will hopefully find patients 
were ideal PFO closure is safe and with long-term data support-
ing decreased stroke risk and complications. At the present time, 
patients should be thoroughly evaluated and risk stratified before 
considering closure of PFO in ESUS.
Furthermore, current evidence-based guidelines do not 
recommend anticoagulation over antiplatelet therapy in patients 
with PFO (46). A large randomized control trial evaluating 
outcomes in PFO patients with anticoagulation vs. antiplatelet 
therapy with aspirin reported a 2-year event rates of 9.5% in the 
warfarin-treated group and 17.9% in the aspirin-treated group, 
but could not conclude statistical significance (HR, 0.5; 95% CI, 
0.2–1.7). In addition, there was no significant difference between 
patients with isolated PFO, those associated with an atrial septal 
defect, or among small or large PFO’s (52). More recently, an 
individual participant meta-analysis evaluating oral anticoagula-
tion or antiplatelet therapy in 2385 patients found no statistically 
significant difference in recurrent stroke, TIA, death; or stroke 
alone. Furthermore, subgroup analysis did not find significant 
heterogeneity of treatment effects in both groups, supporting the 
finding (53).
Considering a real-world experience of all treatment modalities, 
a recent analysis evaluated the net long-term benefit of different 
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therapeutic strategies in patients with CS and PFO encompass-
ing 3311 patients with ≥12  months of follow-up from both 
randomized and observational studies. Although anticoagulation 
therapy was more effective than antiplatelet therapy in preventing 
recurrent stroke and/or transient ischemic attack (event rates: 7.7 
vs. 9.8%, respectively, p = 0.03), there was a sixfold greater risk of 
major bleeding (7.1 vs. 1.3%; odds ratio 6.49, 95% CI, 3.25–12.99, 
P < 0.00001). PFO closure was associated with 50% relative risk 
reduction of stroke and/or TIA vs. antiplatelet therapy and 82% 
relative reduction of major bleeding vs. anticoagulant therapy 
(54). Based on the current state, appropriate risk stratification, 
evaluation of individual stroke risk factors, and tailored therapy 
considering evidence-based guidelines are prudent.
Cardiac Imaging
Trans-thoracic echocardiography (TTE) and trans-esophageal 
echocardiography (TEE) are conventionally used to detect 
intra-cardiac sources of thrombi when investigating embolic 
stroke (55). TEE should be considered in patients with ESUS 
given its higher detection rate of valvular abnormalities includ-
ing vegetation’s left atrial and ventricular thrombus, left atrial 
enlargement, and evaluation of the aortic arch irrespective of 
patients age (12). The utility of Cardiac MRI (CMRI) becomes 
important in detecting a cryptogenic source of stroke due to its 
overall greater sensitivity and high specificity in detecting LV 
thrombi, especially in the post MI sub-population (56, 57). CMRI 
is a multimodal technique utilizing a diverse subset of imaging 
such as spin echo, gradient echo as well as flow velocity encoding 
sequences giving enhanced resolution of cardiac anatomy (58). 
The utility of CMRI has been applied to gain enhanced imaging 
details such as fatty infiltration of the right ventricular free wall 
(causing cardiac rhythm abnormalities in right ventricle), evalu-
ation of left and right ventricular cavity size and mass, as well as 
intra-cardiac shunts (59). In addition, a measure of blood flow 
is also obtained allowing the interpreter to objectify the severity 
of valvular regurgitation and stenosis (60). Through myocardial 
radio frequency tagging, a measure of myocardial dynamics can 
be obtained as well (61). The application of CMRI is especially 
valuable in areas pertaining to aortic arch disease (62) allowing 
enhanced visualization of dissection flaps, complex and false 
aortic aneurysms, atherosclerotic plaque, and supra-valvular 
aortic stenosis (63). Cine gradient echo CMR has also been used 
to visualize turbulence that is produced secondary to valvular 
stenosis/regurgitations (64, 65).
In an analysis of the utility of CMRI in etiology of CS, an 
evident or possible cardio-aortic source was found in 27.1% of 
patients. In addition, delayed enhancement-CMR (DE-CMR) 
sequences enabled further detection of potential sources (66). In 
this study, they were also able to show an overall higher sensitiv-
ity of CS detection via detection of an intra-cardiac source with 
CMR when compared to combination modalities such as TEE 
and TTE in detecting cardio-aortic as potential etiological origin 
(67). DE-CMR is also superior to conventional echocardiography 
in detecting transmural scarring, which constitutes an independ-
ent risk factor for LV mural thrombus when accompanied with 
LV wall motion abnormalities (68, 69). Despite advantages of 
CMR over conventional echocardiographic modalities, potential 
limitations decreasing its utility include cost of acquisition as well 
as relative paucity in availability (66, 70).
vascular Substenotic Atherosclerosis
Substenotic atherosclerotic plaques can possibly cause ischemic 
stroke by plaque rupture and artery-to-artery embolization. In 
particular, complicated atherosclerotic plaques with evidence of 
intraplaque hemorrhage on imaging have been suggested to be 
a potential mechanism in CS. Several modalities are currently 
used to detect complicated atherosclerotic plaques including 
high resolution magnetic resonance angiography (MRA). One 
study showed that complicated atherosclerotic carotid plaques 
with evidence of high intensity signal consistent with intraplaque 
hemorrhage in the internal carotid artery on MRA were present 
in approximately 25% of patients with CS and were more likely 
to occur ipsilateral vs. contralateral to the infarct (68). This 
finding was also confirmed by another study using the same 
imaging modality (71). These studies suggest that substenotic 
plaques with intraplaque hemorrhage may constitute a seperate 
mechanism in CS.
Furthermore, high resolution MRA with vessel wall imaging 
may be helpful in diagnosing intracranial atherosclerotic plaques. 
Diffuse enhancement of the vessel wall may be useful in diag-
nosing an active intracranial atherosclerotic plaque even in the 
absence of luminal narrowing, which may be a potential etiology 
in CS (12). The cost effectiveness of using advanced imaging 
modalities to look for complex, non-stenosing atherosclerotic 
plaques remains unclear. Moreover, their routine use remains 
controversial, especially since antiplatelet agents and statins are 
the mainstay of treating atherosclerotic-type strokes similar to 
treatments used in most patients with CS.
Aortic Arch Atherosclerosis
Aortic arch atherosclerosis (AAA) has been considered a risk 
factor for ESUS and CS. Complex plaque analysis during post-
mortem studies have demonstrated ulcerated aortic arch plaques 
covered with thrombi as well as cholesterol plaques as a nidus for 
embolism (72). Various studies demonstrated a direct correlation 
between AAA plaque size, characteristics, and stroke risk. Plaque 
size of 4 mm (RR of 4.7), mobile and/or complex plaque carry 
increased risk of embolism (46, 72). In particular, a dramatic rise 
in hazard ratio from 3.3 to 13.8 for AAA >4 mm in causing ESUS 
has been reported (73).
The Stroke Prevention in Atrial Fibrillation (SPAF) Echo trial, 
a meta-analysis of case–control case as well as postmortem series 
reported a significant odds of stroke in patients with severe AAA 
(3.76; 95% CI, 2.58–5.48) (74). In addition, AAA was found to 
be far more frequent and relatively higher in severity in patients 
>55 years. Additional systemic risk factors that influence AAA 
progression include cigarette smoking, diabetes, hypertension, 
and hypercholesterolemia (72). Vascular disease such as carotid 
atherosclerosis as well as peripheral vascular disease can serve as 
surrogate markers of AAA development risk due to an increased 
atheroma load (74).
Moreover, studies found a greater degree of embolic signals to 
the brain in patients with severe AAA compared to patients that 
did not (75–77). Atheroma from the mid-to-distal aortic arch has 
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been reported to embolize to the left carotid artery territory. This 
has been suggested through studies using transcranial Doppler 
in identifying microembolic signals reaching the middle cerebral 
arteries compared to patients who did not have AAA-mediated 
emboli (75, 76).
Atherosclerotic plaques located in distal aortic arch also carry 
a potential risk for ESUS. A causative mechanism is amplified 
during diastole with retrograde blood flow from descending 
aorta reaching the major aortic branches in over 24% of patients 
with ESUS (78). While the relationship between AAA and ESUS 
has been reported in various trials, it is noteworthy to mention 
this relationship has been elucidated by only few studies with 
variable criteria in patient selection and definition of significant 
lesions (73, 76, 79–83). However, AAA should be considered as 
a cause of ESUS due to its relatively higher presence when com-
pared to cervical artery atheroscelortic disease, especially after an 
extensive disease fails to demonstrate other arterial and cardiac 
causes (76, 84).
Thorough radiographic images of the aortic arch to investigate 
the extent of atherosclerotic changes as well as plaque charac-
teristics such as thickness and degree of ulceration are needed. 
TEE, done primarily using two-dimensional as well as enhanced 
three-dimensional real time option give detailed representation 
of aortic plaque morphology and location (85). CT angiography 
(CTA) or MRI of the aortic arch may also be obtained. Besides 
providing a higher degree of resolution and being less invasive, 
additional details of the descending and abdominal aorta and 
its branches are visualized (86, 87). Conventional diagnostic 
catheter-based angiography is less applicable due to an overall less 
sensitivity for plaque detection and danger of plaque emboliza-
tion during instrumentation (88).
In the PFO in Cryptogenic Stroke Study (PICSS), TEE detec-
tion of large plaques or complex morphology of aortic arch ath-
eroma among patients with ESUS was associated with an overall 
increased risk of recurrent ischemic stroke or death over a 2-year 
follow up (HR, 6.42; 95% CI, 1.62–25.46) and (HR, 9.50; 95% CI, 
1.92–47.10), respectively (89).
There is an overall paucity of conclusive data that suggests a net 
benefit of anticoagulation over anti-platelet therapy or vice versa. 
A retrospective study examining the effects of treatment on severe 
thoracic aortic plaques showed statin therapy (OR, 0.3; 95% CI, 
0.2–0.6) but not warfarin (OR, 0.7; 95% CI, 0.4–1.2) or anti 
platelet therapy (OR, 1.4; 95% CI, 0.8–2.4) contributed toward 
decreasing risk of stroke, TIA, and peripheral embolization (90). 
Earlier studies suggested anticoagulation with warfarin decreased 
risk of recurrent stroke in patients with mobile thoracic atheroma 
(91) and benefit of anticoagulation over antiplatelet treatment in 
preventing recurrent strokes and peripheral embolic event in 
patients with aortic plaques >4 mm (92).
However, a prospective, randomized, controlled, open-labeled 
trial with blinded endpoint evaluation comparing the efficacy of 
aspirin plus clopidogrel to warfarin in patients with ischemic 
stroke, transient ischemic attack, or peripheral embolism with 
plaque in the thoracic aorta >4  mm, and no other identified 
embolic source was completed. Aspirin plus clopidogrel had a 
non-significant 24% reduction in the rate of recurrent stroke, 
myocardial infarction, peripheral embolism, and vascular death 
(adjusted P =  0.5) but significant reduction in vascular death 
compared with patients on warfarin (log-rank, P = 0.013). The 
results, while showing a marginal benefit of dual anti-platelet use 
over warfarin in preventing cerebral infarction, were not statisti-
cally significant rendering inconclusive results as the study was 
stopped prematurely (93).
Nevertheless, patients with aortic arch atheroembolization 
should be treated for secondary prevention with a combination 
of risk factor lowering strategies targeted at blood pressure, lipid 
control, and efficient glycemic control (94). Current guidelines 
recommend antiplatelet and statin therapy for patients with 
ischemic stroke or TIA and aortic arch atheroma, uncertainty 
of the effectiveness of anticoagulation in contrast to antiplatelet 
agents and no role for surgical endarterectomy (46).
Other Arterial Causes
Subtle luminal irregularities within the vascular distribution of 
an ischemic infarct should be carefully evaluated in ESUS and 
CS. Cervicocephalic large vessel dissections may account for up 
to a quarter of strokes in young adults under the age of 45 years 
(95). Of importance, the majority of dissections are spontaneous 
therefore lack of trauma history should not rule out dissection as 
a possible etiology. MRA with T1 fat saturation can show intra-
mural blood and expansion and therefore should be considered 
in patients with suspected dissection (96).
Varicella Zoster Virus (VZV)-related vasculopathy has a 
broad clinical spectrum of conditions including TIA, ischemic 
strokes, hemorrhagic infarcts, aneurysm formation, and intra-
parenchymal and subarachnoid hemorrhage due to both large 
and small vessel vasculitis (97). Approximately 40% of transient 
cerebral arteriopathy and a third of ischemic stroke of arterial 
origin in the pediatric population are attributed to VZV (98, 99). 
In addition, up to a third of adults who had VZV infection may 
suffer a stroke within 1 year of infection (100, 101). Large vessel 
unifocal vasculopathy is more commonly observed with zoster-
ophthalmicus, while both large and small vessel vasculopathy 
is seen win immunocompromised patients (102). In a study of 
30 patients with VZV vasculitis, 97% had abnormal brain MRI 
with the majority of ischemic changes involving the deep struc-
tures such as basal ganglia (102). Only 63% of patients manifested 
a skin rash, and angiographic evidence of arterial stenosis was 
present in 70% of the cases (37% only small vessels, 13% only 
large vessels, and 50% had mixed presentation) (102).
In patients with CS, history of VZV infection (particularly 
in the ophthalmic distribution) or immune-compromised state 
should prompt evaluation. Serologic testing of CSF should 
include VZV IgG (93% sensitive) as DNA-PCR sensitivity is low 
(30% sensitive) (102). Diagnosed cases of VZV vasculopathy 
should be treated with 10–15  mg/kg acyclovir for a minimum 
of 14 days (97). Adjunct steroid treatment (1 mg/kg Prednisone) 
can be considered without taper for 5 days but not to be extended 
beyond 1 week due to possibility of potentiation of viral infec-
tion. In cases not responsive to acyclovir therapy, prolonged 
valacyclovir 1gm TID dosing for 1–2 months may be considered 
(97). Other infectious causes for stroke such as neuroborrelosis 
or syphilis are rare but should also be considered in patients with 
CS or ESUS based on history and clinical findings.
TABLe 4 | implicated hypercoagulable states in stroke (103, 104, 104).
Prevalence Probable Possible equivocal
inherited hypercoagulable states
Coagulation 
proteins defects
0–21% Fibrinogen level, prothrombin 
G20210A variant factor V Leiden, 
protein C, protein S, Antithrombin III
Factor VIII level Factor XII,  
Factor XIII, 
vWF Smal 
polymorphism  
in intron 2
Fibrinolytic 
system defects
0–2.7% Plasminogen activator inhibitor type 1
Tissue plasminogen activator
Platelets 
hyper-reactivity
No evidence – – –
Biochemical Difficult to identify direct 
contribution due to 
multifactorial process
Hyperhomocysteinemia, MTHFR 
c677t
C-reactive protein, lipoprotein a, paraoxonase 1, endothelial  
nitric oxide synthase, apo-lipoprotein, transforming growth  
factor B1, P-selectin angiotensin converting enzyme, P-selectin
Acquired hypercoagulable states
Not enough data based 
on studies
Oral contraceptive pills, hormone 
replacement therapy, history of 
idiopathic venous thrombosis, 
malignancy
Thrombotic thrombocytopenic purpura, heparin-induced 
thrombocytopenia
Others
5–20% Antiphospholipid syndrome
5–10% Myeloproliferative disorders
Sickle cell anemia (15%), 
Sickle-C disease (2–5%), 
Sickle cell trait (1.5–2%)
Sickle cell disease
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Hypercoagulable States
Hypercoagulable states have a reported prevalence of 3–21% in 
ischemic stroke (103). Inherited coagulopathies most commonly 
invoke venous thrombosis (104, 105). Antiphospholipid anti-
bodies and homocystienemia involve both arterial and venous 
systems as compared to other pro-coagulant states. In patients 
with idiopathic or recurrent thrombophilia manifesting in 
cerebral ischemic events, a diagnostic work-up is warranted. The 
different mechanisms contributing to a hypercoaguable state with 
corresponding testing in a hierarchical manner corresponding to 
the degree of evidence is depicted in Table 4.
The prevalence of stroke related to polygenic and acquired risk 
factors is accelerated with age, albeit this association is reversed 
in monogenetic mutations (104). Typically, age <60, history of 
minimal traditional vascular risk factors, recurrent unprovoked 
venous and arterial thrombotic events, and positive family his-
tory in a patient profile would increase the yield for a positive test 
(103, 104, 106). Furthermore, measuring homeostatic factors at 
the time of hospitalization can be of less diagnostic yield owing 
to the derangement of the otherwise normal metabolic profile 
of a patient in the setting of acute illness (i.e., thrombotic state, 
hepatic disease, renal disease, traumatic-acute stress, sepsis, 
malignancy, malnutrition, pregnancy, anticoagulation medica-
tion use) (107). In addition to clinical criteria, positive antiphos-
pholipid antibodies (lupus anticoagulant, anticardiolipin, or 
anti-beta-2-glycoprotien) require repeated testing 12 weeks later 
to confirm antiphopsholipid syndrome (108). Testing of Factor V 
leiden mutation and Prothrombin gene mutation can be per-
formed immediately during hospitalization; however, measuring 
levels of protein C, protein S, or antithrombin deficiency should 
be deferred 2–3 month after hospitalization or when patients are 
not on anticoagulation (109, 110). Despite limited evidence of 
prophylactic therapy, once the diagnosis is confirmed anticoagu-
lation for inherited thrombophilia may be considered as directed 
by current guidelines and recommendations (American Heart 
Association-Level IIa, Class C) (111).
Stroke Related to Cancer
Ischemic stroke incidence can be as high as 15% in patients with 
malignancy, of which only 50% are identified (112). Trousseau 
syndrome refers to spontaneous recurrent or migratory episodes 
of arterial emboli due to non-bacterial thrombotic endocarditis, 
venous thrombosis, or both in a patient with an underlying 
malignant neoplasm. Several biochemical processes related to 
the hypercoagulable state of malignancy have been suggested. 
These include change in the homeostatic property of blood and 
blood vessels that involve activation of cell adhesion molecules 
by mucin secreted from adenocarcinomas (113, 114), release of 
tissue factors by cancer cells causing activation of factor VII and X 
(115–118), endothelial cell damage from procoagulant cytokines 
such as TNF-alpha, IL-1, and IL-6, which cause vWF release (117, 
118), platelet activation, protein C inhibition (119), intravascular 
lymphomatosis (120), and increased viscosity observed in myelo-
proliferative disorders (121).
Occult cancer as a cause of CS should be considered once 
traditional risk factors have been ruled in patients with sugges-
tive clinical history, advanced age, or familial cancers. In a study 
comparing MRI findings of stroke in cancer patients with the 
general population, the rate of multiple territory infarcts was 
fourfold higher. In addition, gastrointestinal cancer had strong 
correlation with embolic strokes (122). Perhaps multiple terri-
tory infarctions may serve as a potential radiographic marker of 
underlying malignancy in high-risk individuals with ESUS or CS. 
Owing to the heterogeneity of malignancy subtypes, there is 
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currently no standardized approach to screening. However, 
based on individual patient profiles and contributing risk fac-
tors, cancer screening should be individualized. Age appropri-
ate cancer screening modalities, D-dimer, sedimentation rate, 
C-reactive protein, and CT scan of Chest, Abdomen, and Pelvis 
are some of the most commonly used techniques for the malig-
nancy workup (123).
While recognizing that there is limited evidence for stroke 
prevention in cancer-related hypercoagulability states, it 
becomes imperative to establish a rapid diagnosis of the underly-
ing malignancy to intimate appropriate therapy. Anticoagulation 
therapy in patients with malignancy-related hypercoagulable 
state is effective and decreases D-dimer levels over time; a 
surrogate marker for hypercoagulability in malignancy (124). 
The use of antiplatelet agents instead of anticoagulation if the 
pattern of strokes resembles small vessel related infarcts has 
also been documented (123). However, prophylaxis of venous 
thromboembolic events in cancer patients with low-molecular 
Heparin (LMWH) has some reported degree of superiority of 
over Warfarin (123, 125).
Other Potential Causes
Migraine
A pooled analysis of studies analyzing the correlation between 
migraines and stroke demonstrated a RR of 2.04 (95% CI, 
1.72–2.43) (126) with an exacerbated risk in the migraine with 
aura subtype. Gender correlations in women who experience 
migraines have shown an overall higher risk of strokes than 
men (127). Nevertheless, a relationship between men and the 
elderly who experience migraines and strokes also exists (128). 
Other recognized risk factors in patients with migraines causing 
an increased risk of stroke include frequency of attacks (more 
than weekly), absence of nausea/vomiting, age >45  years, his-
tory of smoking, and oral contraceptive use (127, 129–131). 
In the Oxford Vascular Study, 37% of strokes and TIA’s in a CS 
population (over 1000 patients) had associated migraines (with 
or without auras) (132). Moreover, a strong link between patients 
older than 65  years of age with fewer vascular risk factors, no 
family history of stroke, and elevated frequency of migraines to 
have a high degree of ESUS (132). Potential mechanisms explain-
ing the link between migraines and strokes have spanned from 
the presence of anatomical variants of circle of Willis, basilar 
hypoplasia, infratentorial lacunar lesions (133) to disturbances 
in the cortical excitability, cortical depression, and trigemino-
vascular system activation (134). Other potential risk factors 
highlighted in literature as a causative link between migraines 
and strokes include hypercoaguable states, hypoperfusion, and 
PFO’s. The relationships between PFO’s and stroke in migraine 
have been looked upon extensively (35, 135, 136). One poten-
tial mechanism is thought to be related to paradoxical emboli 
across the PFO going ultimately to the brain, also triggering 
migraines (137). However, trials for PFO closure as a potential 
source of decreasing migraines showed an overall lack of such an 
association (138–140).
Infarcts in patients with migraine have a predilection for 
the posterior circulation, and most commonly are silent, small, 
multiple, located within the vascular borderzone location in 
the cerebellum, and more prevalent in patients with aura (141). 
A migrainous infarction is defined as one or more migrainous 
aura symptoms typical for a previous attack lasting >60 min in 
a patient with migraine with aura, associated with an ischemic 
brain lesion in appropriate territory demonstrated by neuroimag-
ing not attributed to another disorder (142). Migrainous infarc-
tion incidence represents 0.5–1.5% of all ischemic stroke but up 
to 10–14% in of ischemic stroke in the young (143). Recognition 
of such infarcts is important particularly in women with frequent 
migraine with aura, posterior circulation territory location and 
no identifiable cause after thorough investigation.
The Womens Health study highlighted the beneficial role 
of aspirin in reducing the risk of ischemic stroke in patients 
with migraines (RR 0.76; 95% CI, 0.63–0.93). This benefit was 
especially seen in women more than 45 years of age and aspirin 
should be considered in these patients. Due to reports highlight-
ing the relationship between PFO’s, migraines, and ESUS, the 
Migraine Intervention with STARFlex Technology (MIST) trial 
was completed but failed to show any benefit of PFO closure on 
cessation of migraine headaches (138). In addition, various tri-
als as well as a recent meta-analysis failed to show a conclusive 
association between PFO and migraines (140, 144, 145). Thus 
far, data is quite limited on evidence of migraine prophylaxis 
and reduction of stroke risk (146). Ultimately practice guidelines 
in primary prevention of stroke in patients with migraines have 
thus stressed smoking cessation in women with migraines of the 
aura subtype (WMA), avoidance of oral contraceptive agents with 
estrogen in WMA, treating to reduce migraine frequency, and 
no clear benefit of PFO closure as a means to prevent strokes in 
patients with migraines (146). It should be noted, however, that 
the epidemiological studies examining PFO closure, migraines, 
and CSs predominantly involved elderly population and failed 
to include younger patients more exclusively. Therefore, for now 
adequate management of hypertension, hyperlipidemia, and 
diabetes mellitus in patients with migraines is recommended 
by the American Headache Society (128, 147–151). In addition, 
patients suffering from cardiovascular disease, hemiplegic, or 
basilar migraines should also avoid vasoconstrictive drugs such 
as triptans and ergotamines (128, 147–151).
Fabry Disease
Fabry disease and inherited progressive X-linked disorder of 
glycosphingolipid metabolism due to alpha-galactosidase A 
(alpha-Gal A) deficiency represent approximately 1% of all stroke 
in the young but between 3 and 5% of CS (152). Patients typi-
cally are younger males and exhibit a constellation of symptoms 
including neuropathy, angiokeratomas, cardiovascular, renal, 
and neurological manifestations (153–156). Ischemic strokes 
in Fabry disease have a predilection to the posterior circulation 
and are associated with vertebrobasilar dolichoectasia (157). 
Vasculopathy and arteriopathy in Fabry disease may manifest as 
TIA’s, strokes, aneurysms, and occular symptoms such as blindness 
(158–163). Ischemic stroke is the predominant subtype (5.6%) 
with mean age <30 and <45 in men and women, respectively 
(164, 165). Serum measurement of leukocyte alpha-Gal A activity 
is standard in most laboratories as work up for Fabry’s disease. 
However, the sensitivity of the test varies in males and females; 
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being almost 100% in males but positive in only 50% of female 
carriers and hemizygous males (166, 167). Antiplatelet therapy, 
enzyme replacement therapy (ERT), and risk factor modification 
are the mainstay secondary preventative measures of treatment in 
Fabry disease. Kidney transplantation may be considered in very 
advanced cases with complications arising from CKD (168–171).
Homocysteine
The relationship between hyperhomocysteinemia (HHC) and 
ESUS remains relatively underexplored, and often with contra-
dictory results (172–174). In a study examining the relationship 
between HHC and stroke, patients with CS had moderately 
elevated levels of homocysteine when compared to controls. 
However, this effect was nullified when cardiovascular risk fac-
tors were adjusted (175). In other studies, a neutral association 
of HHC with CS has also been reported (172, 176). Some suggest 
HHC serves as a marker for atherosclerosis, as well as other 
cardiovascular risk factors leading to stroke (172). A relation-
ship of HHC and CS is, however, amplified in the presence of 
obesity (175, 177–179). This observation is potentially explained 
due to increased oxidative stress parameters and obesity-related 
hormones, which would amplify HHC as a causative agent (175).
Elevated levels of homocysteine can be attributed to multiple 
causes. Genetic defects in cystathionine beta synthase and meth-
ylenetetrahydrofolate reductase (MTHFR) can result in homo-
cysteine level elevation. Decreased renal clearance, especially in 
patients with chronic kidney disease can also contribute toward 
elevated HC levels (180). In addition, nutritional deficiencies 
encompassing Vitamin B6, Vitamin B12, and Vitamin B9 (folate) 
can also cause elevations in HC (181–183).
Conflicting data exist on treatment of elevated homocysteine 
levels by vitamin supplementation. A meta-analysis of 26 rand-
omized controlled trials that found a trend toward decreased stroke 
risk (RR 0.93; 95% CI, 0.86–1.00) in patients supplementing with 
folic acid (184). Similarly, in the HOPE 2 study, a combination of 
Vitamin B6, B12, and Folic acid did lower plasma HC levels and 
reduced stroke risk by 25% (RR 0.75; 95% CI, 0.59–0.97) (185). 
However, despite the somewhat positive results of the aforemen-
tioned trials regarding vitamin supplementation and stroke risk, 
the overall bulk of trials thus far examining the effect of Vitamin B 
complex vitamin and risk of stroke are inconsistent. Nevertheless, 
treatment of HHC with Vitamin B and folate supplementation 
strategies to reduce overall ischemic stroke risk should be consid-
ered, but with an overall undetermined efficacy (146).
Other Genetic, Autoimmune, or  
Rheumatologic Causes
Although the reported prevalence of an underlying genetic 
abnormality as the cause of ischemic stroke is quite low (<1%), 
early identification of a genetic abnormality may have relevant 
implications for management and future counseling (186). More 
importantly, the true prevalence in ESUS or CS is unknown. For 
patients with stroke at a young age, positive family history, and 
absence of conventional risk factors, there is higher probability 
of a genetic cause and yield of testing (187). It may be prudent 
to consider genetic entities (e.g., monogenic vessel diseases) in 
selected individuals.
One should consider Susac syndromes when ocular manifes-
tations predominant and occur on a recurrent basis (188, 189). 
The typical triad of this autoimmune endotheliopathy consists of 
encephalopathy, branch retinal artery occlusion and hearing loss 
(190). The disease manifests more in young women (22–42) and 
the age range overall can affect patients from 7 to 72 years of age 
(190). Strokes commonly involve the corpus collosom.
Up to 20% of SLE patients suffer from stroke with further 
studies elucidating its relationship after controlling for age and 
gender with an odds ratio of 1.5 (191–193). Antiphospholipid 
antibody (APa) syndrome tends to be the most frequent condi-
tion associated with arterial hypercoagulability manifesting as 
thrombocytopenia, livedo reticularis (Sneddons syndrome), pre-
eclmapsia, and still birth (190). Additional mechanisms of strokes 
can be secondary to accelerated atherosclerosis, Libman–Sacks 
endocarditis, elevated homocysteine, and vasculitic mechanisms 
(194–196). Other autoimmune and rheumatologic conditions 
affecting the intracranial and/or extracranial vasculature (e.g., 
Giant cell, Takayasu’s, Polyarteritis nodosa, Kawasaki’s, micro-
scopic polyangiitis, Eosinophilic granulomatosis, Behcets’s, 
Cogan’s syndrome, granulomatosis with polyangiits, Sarcoidosis, 
etc.) are beyond the scope of this chapter and discussed elsewhere 
(197). However, these should be considered in the evaluation 
of patients with CS with subtle luminal irregularities and sug-
gestive symptoms, clinical features, or positive serology during 
evaluation.
Diagnostic Work-Up
The first step in evaluation of a patient with ESUS would be a thor-
ough physical exam including evaluation of the skin and careful 
review of personal and family history. Appropriate classification 
is mandatory as the yield; cost and extent of the diagnostic work-
up will vary. In the absence of conventional risk factors and in 
patients with ESUS, ancillary testing such as use of TEE, CMRI 
is required for cardiac imaging. Prolonged cardiac monitoring 
should be considered in all patients with ESUS. Patients with a 
PFO should have lower extremity ultrasonography and/or MRV 
of the pelvis. Sub-stenotic arterial lesions require careful evalua-
tion including MRA, T1 fat saturation (if dissection is suspected), 
or conventional catheter angiography if subtle or multifocal 
irregularities are found, particularly in younger patients.
Patients with associated systemic manifestations suggesting 
infectious or inflammatory conditions may require CSF examina-
tion. Appropriate screening for hypercoagulable state in younger 
patients with recurrent thrombosis or family history may be 
appropriate. Multi-vessel territory infracts in older patients with 
suggestive individual profiles or clinical history may require 
investigation for malignancy. A suggested investigative approach 
for patients with ESUS is illustrated in Figure 1.
Management
As stroke is >80% preventable, patients with any conventional 
stroke risk factors must be adequately managed to prevent 
recurrence. Treatments pertaining to the specific conditions in 
this article have been discussed. However, antiplatelet therapy 
remains the mainstay for antithrombosis in ESUS and CS at 
the present time. Two randomized clinical trials are currently 
FiGURe 1 | Suggested investigative approach for patients with eSUS.
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investigating the use of novel oral anticoagulants in ESUS patients 
as compared to antiplatelet therapy. The RE-SPECT ESUS trial 
compares dabigatran 150 or 100 mg twice daily to aspirin 100 mg 
daily for secondary prevention in a double-blinded fashion 
with a follow-up period of up to 3  years (198). Similarly, the 
NAVIGATE ESUS trial will compare rivaroxaban 15 mg daily to 
aspirin 100 mg daily for secondary prevention in patients with 
ESUS (199). These trials and similar future trials are needed to 
establish the best treatment modality for patients with ESUS and 
non-ESUS CS stroke patients.
Future Directions and Conclusion
A novel and relatively underexplored area of research into 
identifying stroke etiology has been analysis of clots (thrombus) 
mechanically retrieved after endovascular therapy for stroke. 
Understanding thus far has been limited due to the relative nov-
elty of these procedures and an overall lack of standardization or 
supporting clinical trials, until recently.
Marder et al. (200) presented one of the first clot analysis stud-
ies in 2005 and indicated that histologic analysis of clots retrieved 
from large intracerebral vessels might point toward the etiology 
of stroke. The study could not reach to a statistically significant 
conclusion due to low sample size. The results were also affected 
as the study was done using MERCI device (an older generation 
device), which disrupts clot architecture significantly. Since 2005, 
newer generation devices and corresponding clinical trials have 
shown with enough evidence, the efficacy of these devices in suc-
cessful clot retrieval. A recently published study demonstrated 
that higher red cell content in the clot retrieved from acute 
interventional stroke treatment showed correlation with a car-
dioembolic source. Although promising, this study due to the 
low numbers of patients analyzed could not reach a statistical 
conclusion (201). Further histopathological studies are needed 
to help establish standardized clot characteristics correlating the 
embolic source. In turn, this may be a new diagnostic avenue in 
ESUS and CS.
Biomarkers such as CK-MB and BNP have been suggested to 
improve the diagnosis of embolic ischemic stroke in ESUS. In 
one study, high levels of both markers were predictors of acute 
phase embolism in cardioembolic strokes with combined speci-
ficity of 95% and PPV of 88.2% (202). Increased visceral adipose 
tissue has been recently identified as a potential risk factor of 
stroke in ESUS. Increased VAT was found in over half of patients 
with ESUS in on study and was more common than any other 
conventional stroke risk factor (203). More recently, PET scan-
ning with a fibrin-binding probe tracer injected after thrombosis 
has been shown to successfully detect multiple thrombi both 
venous and arterial in rats, with accurate composition. Probe 
uptake was greater in younger vs. older clots (204). Perhaps a 
future role for such technology would include stroke patients, 
investigating the proximal source of a distal thrombus soon after 
ischemic stroke.
These future investigations may help establish the true source 
of embolism and therefore appropriately dictate treatment. 
However, for patients with truly CS further clinical trials are 
needed for optimal management and secondary prevention.
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